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lization and outcomes. Each factor was rated by three independent reviewers on a 
scale from 1 to 5, with 1 being limited use in economic modeling and 5 being highly 
useful for health economic modeling. Ratings were summed for each reviewer and 
averaged to produce a score out of 20 possible points. Results: Of the 14 real-world 
data sets assessed for utility in health economic modeling, claims data rated highest 
(15 out of 20) due to the availability of patient-level data from multiple sites of care, 
but lacked a link between utilization and patient outcomes. Despite the availability 
of patient outcomes associated with utilization with EMR data, the data set was rated 
the lowest (8 out of 20) due to its lack of nationally representative data and proprietary 
access. ConClusions: Of the currently available real-world data sets, claims data 
was viewed as most useful for health economic models because they include patient-
level utilization data from multiple sites of care. Data mined from EMR represents 
a significant opportunity to link healthcare utilization with patient outcomes, but 
currently available EMR data lacks national representation and is expensive to obtain.
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objeCtives: As more psoriasis treatments come to market in both new and exist-
ing drug classes, health care payers will need assistance in determining the most 
cost-effective regimen or sequence of regimens to control budgets. We sought to 
devise a cost-effectiveness modeling structure that will aid in decision making by 
highlighting differentiating factors between drugs and meet the changing needs of 
payers. Methods: A systematic literature review was conducted to identify previ-
ously published cost-effectiveness models in moderate to severe psoriasis. As part of 
this review, we identified manufacturer submissions to health technology assessment 
(HTA) bodies and HTA responses/critiques of the submissions. The review showed that 
many previous models focused on one line of biologic therapy followed by standard of 
care. Additionally, Psoriasis Area Severity Index (PASI) response was limited in respect 
to both time periods considered and the categories of response modeled. Results: 
We developed a model structure that expanded the treatment/modeling paradigm by 
allowing a sequence of therapies (two lines of biologic therapies followed by standard 
of care). A short-term decision tree allows for a clinical determination of PASI response 
at 12 or 16 weeks post-initiation of therapy. Within the initial 12 or 16 week treatment 
period, we model the change in PASI levels over time to better reflect quality-of-life 
for patients on treatments with better speed of response. Following the decision tree, 
patients enter a semi-Markov (semi-Markov due to time dependent death probabili-
ties) to estimate long-term costs and outcomes. As new drugs allow some patients 
to achieve complete psoriasis clearance, we included a PASI 100 health state. Finally, 
we model disutilities related to severe adverse events to distinguish drugs with bet-
ter safety profiles. ConClusions: This new framework will help decision makers 
by better differentiating psoriasis treatments and determining the optimum order 
of biologic therapies in the psoriasis treatment pathway.
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objeCtives: To calculate national estimates of Necrotizing Enterocolitis (NEC)–
related hospitalization and associated use of health care resources to explore the 
effects of certain patient and hospital characteristics on use of hospital resources 
and length of stay in the United States. Methods: Data from the 2009 Healthcare 
Cost and Utilization Project Kids’ Inpatient Database was used. Pediatric inpatient 
care in 4121 hospitals in 44 US states. Inpatient admissions with an International 
Classification of Diseases, Ninth Revision, Clinical Modification diagnosis of 
Necrotizing Enterocolitis. National estimates of NEC-associated hospitalizations 
were calculated. Potentially significant covariate associations were studied using 
hospital costs and Lengths of Stay as dependent variables. Predictors of high hos-
pitalization cost and prolonged length of stay were evaluated using multivariable 
logistic regression. Results: 2203 NEC-related hospitalizations occurred among 
infants in the United States in 2009, resulting in more than $213 Million in inpa-
tient hospitalization costs. Mean hospital costs and LOS were $110,951 and 51 days, 
respectively. Treatment type, died or not during hospitalization, comorbidities, 
complications, hospital type and hospital region, were significantly associated 
with higher total costs and longer length of stay. ConClusions: For an infant 
disease with a rather low prevalence rate, the estimated annual inpatient pedi-
atric burden of NEC is a sizeable $213.3 million (2009 US$). As surgery treatment 
significantly influenced cost and length of hospitalization, there is an opportunity 
for reduction in inpatient burden if medications and outpatient treatments would 
improve for the treatment of NEC.
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objeCtives: The burden of disease due to seasonal influenza in the United States 
(US) remains high, despite vaccination efforts. In 2003 it was estimated that the 
direct medical costs averaged $10.4 billion, with a total economic burden estimated 
at $87.1 billion. Although the seasonal influenza vaccination is not always a con-
summate match, we suggest that the burden of disease is still greatly reduced 
even when vaccine match to circulating strain is suboptimal. This study aims to 
examine the decreased cost burden associated with the seasonal influenza vaccine, 
even in seasons of suboptimal match, by comparing historic published trends to 
large claims data. Methods: Previously published data were compared to sea-
sonal influenza records, queried from a claims database containing over 55 million 
unique patients. Regression modeling was used to compare cost burden of persons 
and 0.0032 for obese men. Using overweight men as an example, the risk of death in 
this group was higher for diabetics than non-diabetics and increased with age and 
BMI. ConClusions: Our results showed that women had a higher risk of diabetes 
but a lower risk of death for both diabetics and non-diabetics than men. Moreover, 
both risks increased with BMI and age. This joint estimation of the transition prob-
abilities in the Markov model overcomes the problem of negative probabilities 
resulting from separate estimations.
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objeCtives: To develop quality of care (QC) metrics using claims data in hepatitis 
C (HCV) Medicare patients with disability, a vulnerable population facing increased 
access barriers and representing the majority of HCV patients in Medicare, and 
quantify metrics’ correlation with treatment receipt. Methods: We adapted 14 
Veterans Affairs-developed quality metrics (QM) for measurement in a cohort 
of 1,936 disabled HCV patients (2006-2009) with 6 months continuous Medicare 
parts A, B, D enrollment before diagnosis and no previous treatment. Based on 
the machine-learning principle of recursive partitioning, the proposed algorithm 
implements a random forest model of conditional inference trees, identifies the for-
est’s representative tree, and aggregates its terminal nodes into QC patient groups. 
Using linked county-level data from the Area Health Resource Files, we compared 
contextual characteristics across QC groups. Results: On average, 10.4% received 
peg-interferon. The five strongest predictors of treatment included “having received 
liver biopsy”, “HCV genotype testing”, “visit to specialist”, “confirmation of HCV 
viremia”, and “iron overload testing”. High QC (n= 360; treated= 33.3%) was defined 
for patients who had at least 2 from the abovementioned metrics. Good QC patients 
(n= 302; treated= 12.3%) had either “HCV genotype testing” or “visit to specialist”, 
while fair QC patients (n= 282; treated= 7.1%) only had “confirmation of viremia”. 
Patients with low QC (n= 992; treated= 2.5%) had none of the selected QMs. The 
algorithm accuracy of predicting treatment was 70% sensitivity and 78% specificity. 
Compared to those with fair or low QC, more high and good QC patients lived in rural 
or small town areas with lower access to specialized hospital and physician services 
and lower rates of insurance and education. ConClusions: Higher quality of care 
correlated with higher treatment rates. Limited healthcare access among Medicare 
disabled patients with HCV was not associated with lower quality. Future research 
is needed to assess pre-treatment QM with newer HCV therapies.
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objeCtives: Polymorphism of CYP2C19 affects metabolism and drug response of 
clopidogrel. New antiplatelet drugs such as prasugrel and ticagrelor are not affected 
by CYP2C19 polymorphism. CYP2C19 genetic testing could guide the selection of 
clopidogrel versus new antiplatelet agent (genotype-guided therapy). Published 
cost-effectiveness analyses of universal prasugrel or ticagrelor treatment versus 
genotype-guided therapy for patients with acute coronary syndrome (ACS) and 
planned percutaneous coronary intervention (PCI) yet showed conflicting results. 
We aimed to evaluate the cost-effectiveness of the new class of antiplatelet drugs 
versus genotype-guided therapy. Methods: A lifelong Markov model was devel-
oped to compare universal new antiplatelet drugs treatment and genotype-guided 
therapy from the perspective of healthcare provider. In genotype-guided therapy 
arm, patients without CYP2C19 loss-of-function (LOF) allele would receive generic 
clopidogrel, while patients with at least one LOF allele would receive a new anti-
platelet agent. All clinical inputs were derived from published meta-analysis and 
clinical trials. Direct medical costs and quality-adjusted life-year (QALY) gained were 
the primary model outcomes. Results: Base-case results showed that genotype-
guided therapy cost $73,131 with 8.068 QALYs, while universal new antiplatelet 
therapy cost $79,179 with 7.946 QALYs. With a threshold of willingness-to-pay of 
$50,000 per QALY, no threshold values were identified in one-way sensitivity analy-
sis. The most influential factor was the probability of ischemic heart disease (IHD) 
state turned to death, followed by the possibility of post myocardial infarction state 
turned to death, cost of PCI and utility of IHD. In probabilistic sensitivity analysis, 
genotype-guided therapy was dominant with $6192 (95% CI 6170-6214) less costly 
and a gain of 0.2235 QALY (95% CI 0.2234-0.2236) compared with universal new anti-
platelet therapy. ConClusions: Compared with universal use of new antiplatelet 
drugs, genotype-guided therapy seems to be a less costly and more effective clinical 
strategy for patients with ACS undergoing PCI.
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AssessMeNt of CuRReNt dAtA souRCes
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objeCtives: Effective and robust health economic models are built on a foundation 
of reliable, accurate data sets. With the availability of various real-world data sets, 
the objective of this study was to examine several real-world data sets and rate their 
overall utility for use in health economic models in the United States. Methods: 
Real-world data sets included in the assessment were one claims dataset, one elec-
tronic medical record (EMR) dataset, 11 state-level all payer claims databases (APCDs) 
and data from the Healthcare Cost and Utilization Project (HCUP). Factors assessed 
included: coverage of national versus regional population, inclusion of various sites 
of care, free/public access, and availability of longitudinal patient-level data on uti-
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ondary aim of this analysis is to promote an approach to develop more reliable disease 
simulation models in cardiovascular disease. Methods: Data describing LDL-C and 
nfMI+CV Death outcomes were abstracted from several landmark secondary preven-
tion statin trials in clinically stable patient populations (4S, CARE, LIPID, HPS, TNT, 
IDEAL, GREACE, AVERT, and LIPS). Linear (L), quadratic (Q), one-knot linear spline 
(S1L) and two-knot quadratic spline (S2Q) models were fit. RMSE, leave-one-out cross 
validated (LOOCV) and Monte Carlo cross validated (MCCV) RMSE (90% training, 1,000 
replicates) were used to evaluate predictive performance. Predicted event rates based 
on LDL-C = 50mg/dL were estimated to illustrate the clinical implications of each 
model. To encourage full reproducibility and transparency, all raw data and code (R) 
will be made freely available for download online via authors Git repository. Results: 
A total of eight models were fit and evaluated, including four distinct functional 
forms (L, Q, S1L, and S2Q) across two sets of data (all data (A) and data censured for 
high leverage studies(C)). Of all the models evaluated, S2Q-C exhibited the lowest 
RMSE (0.317) while L-C produced both the lowest LOOCVRMSE (0.463) and MCCVRMSE 
(0.389). Model selection had an impact on predicted percentage of events/yr at 50mg/
dL (range= 0.769 to 2.09). ConClusions: This analysis suggests that a linear model 
may be among the most appropriate when describing the relationship between LDL 
and nfMI+CV Death in secondary prevention; however, other models (linear spline 
and quadratic) warrant further investigation. These findings along with additional 
research will help inform more reliable and accurate models of long-term outcomes 
and economic benefit of LDL-C lowering treatment modalities.
PRM66
tHe woRld HeAltH oRgANizAtioN ANd uNiveRsAl diAgNostiC testiNg 
foR susPeCted MAlARiA iN CHildReN: is tHe New PoliCy Cost-effeCtive 
ANd AffoRdABle foR suB-sAHARAN AfRiCA?
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objeCtives: Malaria imposes a substantial global disease burden with 198 million 
cases reported worldwide in 2013. It disproportionately affects sub-Saharan Africa, 
particularly young children and accounts for 14% of the region’s childhood deaths. 
In an effort to improve disease management, the World Health Organization (WHO) 
in 2010 recommended countries test children (age < 5) who present with suspected 
malaria fever and confirm diagnosis rather than treat them presumptively with 
antimalarial drugs, the standard of care to date. While all 47 African countries 
designated as malaria-endemic, have adopted the policy, significant barriers to 
implementation exist. These include costs, uncertainty about the overall health 
benefits, shortfalls in testing supplies and physician practice patterns. Methods: 
We use a decision-analytic approach to assess the policy’s cost effectiveness in three 
countries in sub-Saharan Africa: Angola, Tanzania and Uganda, each representing 
different prevalence/income combinations. Our model includes country-specific 
epidemiologic, cost and behavioral data, including that of physician and caregiver. 
Our primary data sources are national Malaria Indicator Surveys and information 
from each country’s National Malaria Control Program. We use a Markov specifi-
cation to account for multiple fever episodes and estimate the incremental cost-
effectiveness of the testing policy through two-stage micro-simulation models. 
These models capture key dimensions of uncertainty associated with our projec-
tions. Results: We find that diagnostic testing for malaria is cost-saving in Angola. 
In Tanzania the cost per life-year gained is $5.54 and $94.58 in Uganda. Both are cost-
effective compared to the WHO standard of $150 per life-year gained. Our results 
are robust under varying cost, prevalence and behavioral assumptions. Probabilistic 
sensitivity analyses indicate that testing is cost-saving or cost-effective: 80% of the 
time in Angola, 89% in Tanzania, and 69% in Uganda. ConClusions: Our findings 
strongly suggest pursuit of policies that facilitate full implementation of testing, 
including promoting clinician adherence to test results.
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CoMMuNiCAtiNg tHe eCoNoMiC BuRdeN of RARe diseAses
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objeCtives: The concept of whole-disease model has rarely been applied in prac-
tice or considered in the published literature. No studies to date have addressed the 
applicability of this approach in rare diseases. This research aims to demonstrate 
the applicability, technique, and framework of the model designed to educate US 
Payers of the estimated patient-level costs and resource utilization, using a rare 
disease as a case study. Methods: The lack of specific ICD-9-CM code, prevalence 
overestimation, poorly documented US epidemiology data, complex diagnostics, 
and off-label pharmacotherapy were evident in rare diseases. In order to estimate 
patient-level resource utilization, diagnosis costs, and 12-month treatment cost 
from the US Payer’s perspective, a clinical guideline-based approach was developed. 
We reviewed diagnosis and treatment guideline recommendations to develop a 
resource utilization algorithm which was subsequently validated by clinicians to 
reflect the real-world clinical practice. Model cost inputs were derived from pub-
lished resources including the most recent year Medicare Fee Schedules and H-CUP 
National Inpatient Sample database. Adverse event costs associated with the treat-
ments were not accounted for in the model. Results: An interactive, MS-Excel 
based economic model was constructed based on guideline recommendations. The 
model inputs were customizable, allowing flexibility in plan/Payer specific disease 
burden estimation. Cost of diagnosis, pharmacotherapy, and surgical therapies were 
calculated for a single patient over a 12-month period. ConClusions: The study 
demonstrates that the whole-disease model approach can be applied to rare dis-
eases to provide the disease burden estimation, serving as an information tool for 
Payers, for diseases with small patient volume and unknown cost burden. The model 
also provides a platform for manufacturers to: 1) incorporate real-world data as they 
become available; 2) add/remove interventions as the market evolves and; 3) add 
various economic elements to further calculate budget impact or cost-effectiveness 
of an intervention over a product life-cycle.
unvaccinated with the seasonal influenza vaccine and persons vaccinated during 
seasons where vaccine was considered (by the CDC-reported vaccine effective-
ness percentage (VE%= (1-relative risk)*100%)) a suboptimal match for seasonal 
flu strain. Results: Published vaccine effectiveness for a suboptimal seasonal 
influenza vaccination ranged from 39%-63% from flu seasons 2006-2007 through 
2013-2014. This was approximately the same protection observed in the large claims 
database for the same year ranges. When modeled together with cost it was shown 
that this mismatch of vaccination to circulating virus still equated to a substantial 
reduction in burden of disease when vaccinated. Validation of results still ongo-
ing. ConClusions: The burden of disease of influenza significantly decreases 
even when the seasonal influenza vaccine is a suboptimal match to the prevalent 
circulating strain. It is recommended that all persons able to receive the influenza 
vaccination do so, whether or not the match is optimal. It has been demonstrated 
that a suboptimal match effectively decreases the burden of the disease.
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objeCtives: Value of Information (VOI) analyses can help align research investments 
with areas that could have the greatest impact on patient outcomes, but many ques-
tions remain concerning its feasibility and acceptability to inform real-world prior-
itization decisions. Our objective was to develop a process for calculating VOI in “real 
time” to inform trial funding decisions within SWOG, a large cancer clinical trials 
group. Methods: We adapted a novel and efficient modeling approach - minimal 
modeling VOI - using a sample of nine phase II/III trial proposals from the Breast, 
Gastrointestinal, and Genitourinary committees reviewed by SWOG’s leadership 
between 2008-2013. We created decision models for each trial proposal and devised 
an efficient process to characterize prior uncertainty in treatment effect by linking 
evidence-based assumptions in a trial’s sample size calculations with the historical 
success rates of SWOG trials. Expected clinical and economic VOI was calculated using 
Bayesian updating methods. We customized the process using iterative stakeholder 
input. Results: The VOI modeling process was feasible and sufficiently captured key 
expected differences in comprehensive outcomes and attendant uncertainty for 8 of 9 
trial proposals. Model construction and calculations took one researcher < 1 week per 
proposal. We accommodated stakeholder input by: a) deconstructing VOI metrics into 
expected health benefits and incremental healthcare costs, b) assuming treatment 
decisions were based on health benefits alone, and c) providing both individual and 
population level results. Following this customization, SWOG generally accepted the 
VOI framework and results for the retrospective analyses and felt that VOI analyses 
would likely be useful in informing future trial proposal evaluations. ConClusions: 
We developed an efficient and customized process for calculating the expected VOI 
of cancer clinical trials that is feasible for use in real-time decision-making and is 
acceptable to stakeholders. Prospective use and assessment of this approach is cur-
rently underway within SWOG.
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objeCtives: Generating multivariate random variables is essential in disease 
simulation applications. In this study we examine the implications of alternative 
approaches to generate marginal distributions and correlation matrix on simula-
tion outcomes. Methods: We adopt three alternative methods including Cholesky 
Decomposition (CD), CD with conditional matching, and the NORmal-To-Anything 
(NORTA) method to generate a hypothetical simulation sample with arbitrary mar-
ginal distributions and correlation matrix. As the comparator, we also create an 
independent and identically distributed (iid) simulation sample. The samples are 
individually populated in a previously developed type 2 diabetes microsimulation 
model to predict the major clinical endpoints over 15 years. The endpoints include 
all-cause mortality, diabetes-related mortality, and major cardiovascular events. We 
examine the goodness of fit by total deviance, i.e., the aggregated values of the rela-
tive difference between the individual predictions with the endpoints observed in the 
actual data, in the overall and stratified samples. Results: The results show that, 
the model predications deviate from the observed data with an iid sample. Over 15 
years, the model over-predicts all the numbers of endpoint events by 20%, with the 
total deviance of 0.73, and the over-prediction is particularly more pronounced in the 
younger patients. With a sample of a constructed multivariate normal distribution 
using the CD and CD plus conditional matching approach, the deviance is reduced 
to 0.41 and 0.58 respectively. A further improvement is observed when using the 
NORTA method, with the deviance of the endpoints between model prediction and 
actual data further reduced to 0.11. The reduction was mainly contributed by better 
approximations in the dispersion of the risk factors among patients. ConClusions: 
Random sequences generation has important ramification for simulation outcomes. 
Poorly-defined multivariate distributions may significantly distort the simulation 
performance. Given its flexibility for both continuous and discrete variables, NORTA 
method appears to be a preferable approach.
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objeCtives: This study aims to evaluate four alternative models that each describe 
the relationship between LDL-C and CV event rates in secondary prevention. A sec-
